DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, nothing will not stop me except God................DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 25Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK GENERICS at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Tuesday 23 December 2014

4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4- thioxoimidazolidin-l-yl)butanoic acid



Figure imgf000111_0001

Example 14; 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4- thioxoimidazolidin-l-yl)butanoic acid


RU59063 (145 mg, 0.38 mmol) was dissolved in 2 mL DMF, charged with PDC (1.4 g, 3.7 mmol) and stirred for 48 hours, upon which time the mixture was quenched with 10 mL 1 M HCL and extracted into Et20 (5 X 25 mL). The combined organic layers were washed with brine (1 X 100 mL), dried with Na2S04 and concentrated down to yield 135 mg (90% yield) pure product.


H NMR (300 MHz, CDC13) δ 7.94 (d, J= 8.3, 1H), 7.88 (s, 1H), 7.77 (d, J= 8.2, 1H), 3.82 - 3.65 (m, 2H), 2.50 (s, 2H), 2.14 (s, 2H), 1.59 (s, 6H);


13C NMR (126 MHz, CDC13) δ 178.6, 177.4, 175.3, 175.2, 137.1, 135.2, 133.5 (q, J = 32.1), 132.1, 127.0 (q, J= 4.7), 121.8 (q, J= 276.2), 114.9, 1 10.1, 65.2, 43.3, 31.7, 23.1 ;


 LRMS (ESI) 421.2
(M+Na)+.

 http://www.google.com/patents/WO2013170147A1?cl=en









DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK
Join me on twitterFollow amcrasto on Twitter     
Join me on google plus Googleplus

 amcrasto@gmail.com



No comments:

Post a Comment